Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C
β Scribed by A. K. P. Lim; N. Patel; R. J. Eckersley; J. F. L. Cobbold; M. M. E. Crossey; D. O. Cosgrove; R. D. Goldin; H. C. Thomas; S. D. Taylor-Robinson
- Book ID
- 108886384
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 119 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Genetic factors of the host have been shown to influence the outcome of treatment for hepatitis C virus (HCV) infection. Killer cell immunoglobulinβlike receptors (KIR) regulate natural killer (NK) cell activity by interaction with specific human leukocyte antigen (HLA) class I. In this
## Abstract Several factors, including metabolic profile, are predictive of response to standard antiviral therapy in patients with chronic hepatitis C. In a retrospective study, it was investigated whether uric acid, involved in metabolic syndrome, could be included. A total of 153 patients (56.2%
## Abstract Serum hepatitis C virus (HCV) RNA level has been shown to be a good predictor of subsequent response to interferonβΞ± (IFN) therapy in US patients in whom genotype 1a/1b are both predominant. To determine whether serum HCV RNA level is a predictor of subsequent response to IFN in Japanes